Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6-11 Years: A NICE Single Technology Appraisal

Author： Burch Jane  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.30, Iss.11, 2012-11, pp. : 991-1004

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alitretinoin for Severe Chronic Hand Eczema: A NICE Single Technology Appraisal

By Rodgers Mark  

PharmacoEconomics, Vol. 28, Iss. 5, 2010-05 ,pp. : 351-362

Adis International

Access to resources Recommend Favorite

Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal

By McKenna Claire  

PharmacoEconomics, Vol. 30, Iss. 1, 2012-01 ,pp. : 35-46

Adis International

Access to resources Recommend Favorite

Golimumab for the Treatment of Psoriatic Arthritis: A NICE Single Technology Appraisal

By Yang Huiqin  

PharmacoEconomics, Vol. 30, Iss. 4, 2012-04 ,pp. : 257-270

Adis International

Access to resources Recommend Favorite

Omalizumab is an effective add-on therapy in moderate-to-severe allergic asthma

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 7, 2005-07 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

NICE no longer recommends omalizumab for asthma . . .

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 667, 2012-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite